GO Main Menu Go Main Contents Go Bottom Menu
  • 44
    Celltrion Healthcare showcases positive 1-year res..
    Celltrion Healthcare showcases positive 1-year results for novel subcutaneous formulation of infliximab in patients with active Crohn’s disease and ulcerative colitis presented at The European Crohn's and Colitis Organisation (ECCO) annual congress…
    2020-02-14
  • 43
    ‘First Mover to Game Changer’: Celltrion announces..
    ‘FirstMover to Game Changer’: Celltrion announces 2020-2030 strategy at the 38thJ.P. Morgan Healthcare Conference ·Celltrion’s Chairman JungJin Seo announced the company’s strategy for the upcoming decade including itsbiosimilar, bioinnovative …
    2020-01-16
  • 42
    Celltrion Healthcare receives EU marketing authori..
    Celltrion Healthcare receives EU marketing authorisation forworld’s first subcutaneous formulation of infliximab, Remsima SC™, for thetreatment of people with rheumatoid arthritis ·Remsima SC™ is thesubcutaneous version of Celltrion Healthcare’s…
    2019-11-26
  • 41
    New data show non-inferiority of efficacy for subc..
    New data show non-inferiority of efficacy for subcutaneous formulation of CT-P13 (biosimilar infliximab) to intravenous formulation of CT-P13 in people with rheumatoid arthritis · The results after switching from intravenous (IV) to subcutan…
    2019-11-09
  • 40
    New subcutaneous formulation of Celltrion Healthca..
    New subcutaneousformulation of Celltrion Healthcare’s CT-P13 (biosimilar infliximab) showspositive Phase 1 results for the treatment of IBD in data presented at UEGWeek Barcelona 2019 · Results from a multicentre, open-label, randomised Phase 1, p…
    2019-10-18
  • 39
    Celltrion Healthcare receives CHMP positive opinio..
    Celltrion Healthcare receives CHMP positive opinion for novel subcutaneous formulation of CT-P13 (biosimilar infliximab) for the treatment of people with rheumatoid arthritis CT-P13 subcutaneous (SC) (biosimilar infliximab) recommended by CHMP…
    2019-09-22
  • 38
    New Subcutaneous Formulation of Celltrion Healthca..
    Data at 54 weeks showed that the subcutaneous (SC) formulation of CT-P13 was comparable in terms of the efficacy and safety when investigated against intravenous (IV) formulation of CT-P13 (biosimilar infliximab) in rheumatoid arthritis (RA). •The…
    2019-06-12
  • 37
    Celltrion Healthcare showcases initial data from y..
    The subcutaneous (SC) formulation of CT-P13 was comparable in terms of efficacy and safety with intravenous (IV) formulation for the treatment of Crohn’s disease up until week 54, indicating that CT-P13 SC could be a future alternative in…
    2019-03-08
  • 36
    [Notice to shareholders] Celltrion Healthcare’s St..
    [Notice to shareholders] Celltrion Healthcare’s Statement on press release from YTN The following is an official response by Celltrion Healthcare to the press release from YTN titled “The Financial Supervisory Services(FSS) investigation at Celltr…
    2018-12-11
  • 35
    Celltrion Healthcare presents positive results for..
    New two-year data showed that CT-P10 was comparable in terms of overall survival, progression-free survival and sustained response with reference rituximab Data published inTheLancet Haematologydemonstrates therapeutic equivalence of CT…
    2018-12-04